التفاصيل البيبلوغرافية
| العنوان: |
Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial. |
| المؤلفون: |
Clephas, Pascal R D, Zwartkruis, Victor W, Malgie, Jishnu, Gent, Marco W F van, Rocca, Hans-Peter Brunner-La, Szymanski, Mariusz K, Halm, Vokko P van, Handoko, M Louis, Kok, Wouter E M, Asselbergs, Folkert W, Kimmenade, Roland R J van, Manintveld, Olivier C, Mieghem, Nicolas M D A van, Beeres, Saskia L M A, Post, Marco C, Borleffs, C Jan Willem, Tukkie, Raymond, Mosterd, Arend, Linssen, Gerard C M, Spee, Ruud F |
| المصدر: |
European Heart Journal; 8/21/2024, Vol. 45 Issue 32, p2954-2964, 11p |
| مصطلحات موضوعية: |
CARDIAC pacing, PULMONARY artery, VENTRICULAR ejection fraction, OLDER patients, IMPLANTABLE cardioverter-defibrillators |
| مستخلص: |
Background and Aims In patients with chronic heart failure (HF), the MONITOR-HF trial demonstrated the efficacy of pulmonary artery (PA)-guided HF therapy over standard of care in improving quality of life and reducing HF hospitalizations and mean PA pressure. This study aimed to evaluate the consistency of these benefits in relation to clinically relevant subgroups. Methods The effect of PA-guided HF therapy was evaluated in the MONITOR-HF trial among predefined subgroups based on age, sex, atrial fibrillation, diabetes mellitus, left ventricular ejection fraction, HF aetiology, cardiac resynchronization therapy, and implantable cardioverter defibrillator. Outcome measures were based upon significance in the main trial and included quality of life-, clinical-, and PA pressure endpoints, and were assessed for each subgroup. Differential effects in relation to the subgroups were assessed with interaction terms. Both unadjusted and multiple testing adjusted interaction terms were presented. Results The effects of PA monitoring on quality of life, clinical events, and PA pressure were consistent in the predefined subgroups, without any clinically relevant heterogeneity within or across all endpoint categories (all adjusted interaction P -values were non-significant). In the unadjusted analysis of the primary endpoint quality-of-life change, weak trends towards a less pronounced effect in older patients (P interaction =.03; adjusted P interaction =.33) and diabetics (P interaction =.01; adjusted P interaction =.06) were observed. However, these interaction effects did not persist after adjusting for multiple testing. Conclusions This subgroup analysis confirmed the consistent benefits of PA-guided HF therapy observed in the MONITOR-HF trial across clinically relevant subgroups, highlighting its efficacy in improving quality of life, clinical, and PA pressure endpoints in chronic HF patients. [ABSTRACT FROM AUTHOR] |
|
Copyright of European Heart Journal is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder